Intas has a strong and diversified business model of marketing, strategic partnership, hospital/institutional focus and supply agreements in Emerging Markets in 20+ countries with tailored strategies focusing on gaining leadership in generic oncology and critical care.
Intas “sustainable business” model has helped achieve 20% CAGR (FY 2016-Est FY 2022) through purely organic growth. Brazil, South Africa, Mexico and Australian markets contribute to ~80% of the total Emerging Markets sales.
Intas is a leading generic oncology player in the participating markets of South Africa and Australia, with an expanding market share and rapidly rising ranks in Malaysia, Brazil, Thailand & Mexico in participating markets.
Intas has over 190+ INNs registered and a strong pipeline with over 125+ INNs under registration across Emerging Markets. We are poised to accelerate our growth through Oncology, Critical Care, CVS, and CNS therapies as well as BD/In-licensing products including differentiated and complex product portfolios.
Comments
Post a Comment